NHS England (NHSE) has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen (STR) for the treatment of HIV in adults and adolescents.
This decision allows clinicians across England to routinely prescribe Symtuza(darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) on the NHS for eligible patients.
Read more: http://www.pharmatimes.com/news/nhs_england_agrees_to_fund_janssens_symtuza_1254081